Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Core Insights - Cardiff Oncology, Inc. announced positive results from the CRDF-004 Phase 2 clinical trial of onvansertib in combination with standard-of-care for first-line RAS-mutated metastatic colorectal cancer (mCRC), showing a 49% confirmed objective response rate (ORR) in the 30mg dose arm compared to 30% in the control arm [1][2][4] Trial Design - The CRDF-004 trial enrolled patients with documented KRAS or NRAS mutations and evaluated onvansertib added to standard-of-care regimens [3] - Patients were randomized into six arms, including different doses of onvansertib combined with standard-of-care or standard-of-care alone, with primary and secondary endpoints focused on ORR and progression-free survival (PFS) [3] Efficacy Data - The confirmed ORR was 30% for the control arm, 42% for the 20mg onvansertib plus SoC arm, and 49% for the 30mg onvansertib plus SoC arm [4] - At the 6-month mark, the ORR was 22% for the control arm, 33% for the 20mg dose, and 46% for the 30mg dose [4] - Early PFS data indicated a trend favoring the 30mg onvansertib dose compared to the control arm [9] Safety and Tolerability - Onvansertib was well-tolerated among the 104 patients dosed, with no major or unexpected toxicities reported [10] - Grade 3 or higher adverse events were infrequent, with neutropenia being the most common treatment-emergent adverse event [10] Future Outlook - The company plans to engage in discussions with the FDA and advance towards the registrational CRDF-005 trial, with an update on the first-line mCRC program expected by Q1 2026 [11][12]